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Analysis of the Hippocampal Proteome in ME7 Prion Disease
Reveals a Predominant Astrocytic Signature and Highlights
the Brain-restricted Production of Clusterin in Chronic
Neurodegeneration*
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Ayodeji A. Asuni‡1, Bryony Gray‡, Joanne Bailey‡, Paul Skipp§, V. Hugh Perry‡, and Vincent O’Connor‡
From the ‡Centre for Biological Sciences and §Centre for Proteomic Research, University of Southampton,
Southampton SO17 1BJ, United Kingdom
Background: Prion disease causes chronic neurodegeneration via deposition of extracellular misfolded protein akin to
Alzheimer disease.
Results: Proteomic analysis revealed a major nonproliferative astrogliosis encompassing GFAP, EAAT-2, Prdx6, and the acute
phase protein Clusterin.
Conclusion: Brain changes are not reflective of measured circulating Clusterin.
Significance: Our data highlights caution in the use of circulating levels of biomarker as clinical measures of actual
neurodegeneration.
Prion diseases are characterized by accumulation of misfolded
protein, gliosis, synapticdysfunction, andultimatelyneuronal loss.
This sequence, mirroring key features of Alzheimer disease, is
modeled well in ME7 prion disease. We used iTRAQTM/mass
spectrometry to compare the hippocampal proteome in control
and late-stage ME7 animals. The observed changes associated
with reactive glia highlighted some specific proteins that domi-
nate the proteome in late-stage disease. Four of the up-regulated
proteins (GFAP, high affinity glutamate transporter (EAAT-2),
apo-J (Clusterin), andperoxiredoxin-6) are selectively expressed in
astrocytes, but astrocyte proliferation does not contribute to
their up-regulation. The known functional role of these proteins
suggests this response acts against protein misfolding, excito-
toxicity, and neurotoxic reactive oxygen species. A recent con-
vergence of genome-wide association studies and the peripheral
measurement of circulating levels of acute phase proteins have
focused attention on Clusterin as a modifier of late-stage
Alzheimer disease and a biomarker for advanced neurodegenera-
tion. SinceME7 animals allow independentmeasurement of acute
phase proteins in the brain and circulation,we extendedour inves-
tigation to address whether changes in the brain proteome are
detectable in blood.We found no difference in the circulating lev-
els of Clusterin in late-stage prion disease when animals will show
behavioral decline, accumulation of misfolded protein, and dra-
matic synapticandneuronal loss.Thisdoesnotprecludean impor-
tant role of Clusterin in late-stage disease, but it cautions against
the assumption that brain levels provide a surrogate peripheral
measure for the progression of brain degeneration.
Prion disease and Alzheimer disease (AD)2 are among a
number of chronic neurodegenerative disorders in which the
accumulation of misfolded protein is associated with neuropa-
thology (1–3). In prion diseases, the generation of the misfold-
ing insult can be sporadic, genetic, or of an infectious origin (4).
Prion disease progression is characterized by activated micro-
glia, astrogliosis, vacuolation, spongiform degeneration, and
neuronal loss (5), andmany of these neuropathological features
are observed in AD (6). Central to this neuropathology is mis-
folding of plasma membrane-localized cellular prion protein
(PrPc), leading to a predominantly extracellular accumulation
of the conformationally altered isoformPrPSc (7–10). Although
degeneration of neurons is associated with the accumulation of
the misfolded protein, there is significant support for the idea
that both intracellular and extracellularmisfolded proteins play
a pivotal role in the neuron loss in prion and other neurodegen-
erative diseases (11–13).
The degeneration of neurons in prion disease may be a cell
autonomous event or involve interactions with other cells (14).
In prion disease, there is evidence that expression of PrPc in
astrocytes alone is sufficient to support propagation of the dis-
ease progression and neurodegeneration (15). Besides being
implicated in disease pathogenesis, astrocytes have been dem-
onstrated to be neuroprotective (16). Typically, astrocytes con-
tribute to a variety of functions in the brain, including homeo-
stasis, neurotransmission, synapse formation, plasticity, and
metabolism. In AD, the key components of the pathology are
directly sensed by the glial populations that ordinarily support
neuronal homeostasis leading to gliosis with poorly resolved
functional consequences (17, 18).
In prion disease, the well characterized microglial signature
shows that these cells are associated with an inflammatory* This work was supported by Medical Research Council Grant G0501636.
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response but one that is atypical and indicative of cells thatmay
contribute to phagocytic clearance of debris (19, 20). Despite
the anti-inflammatory profile associated with microglia in
prion disease, inhibition of microglia proliferation even at the
onset of disease symptoms can delay the emergence of behav-
ioral deficits, reduce neurodegeneration, and prolong life (21).
To provide a better understanding of the role of different cell
types in prion disease progression, we carried out comparative
hippocampal proteome analysis of control andME7 animals at
late-stage disease using isobaric tags for relative and absolute
quantification (iTRAQTM) andmass spectrometry.Weprofiled
and quantified differences in themRNAand protein expression
of hippocampi from control and diseased animals at selected
time points of disease progression and relate these to previously
described cellular and behavioral dysfunction (22). This analy-
sis suggests that the astrocytes dominate the proteome of dis-
eased animals andmount a complex biochemical response. The
response involves a range of activities that have the potential
to ameliorate protein misfolding (apo-J and Clusterin), glu-
tamate toxicity (EAAT-2), and oxidative stress (peroxire-
doxin-6, Prdx6).
EXPERIMENTAL PROCEDURES
Stereotaxic Injection—These experimentswere carried out in
accordance with the United Kingdom Animals (Scientific Pro-
cedures) Act of 1986 and adhered to ARRIVE guidelines for
reporting experiments involving animals (23). All surgical pro-
cedures were carried out as described previously (24). Briefly,
age-matched female C57BL/6J mice were anesthetized and ste-
reotaxically injected bilaterally into the hippocampus with 1 l
of 10% (w/v) brain homogenate prepared from normal brains
(NBH) or from terminally ill ME7-infected mice. Onset of the
clinical disease was measured weekly by determination of body
weight. NBH- and ME7-infected mice were sacrificed at 8, 13,
and 21 weeks post-injection to characterize early, middle, and
late stages of disease. Mice were housed in a temperature-
and humidity-controlled environment and had free access to
food and water. Animals were terminally anesthetized and per-
fused with heparinized saline solution, and themicro-dissected
hippocampus was frozen on dry ice.
iTRAQ Procedure—We pooled and homogenized hip-
pocampi from NBH and ME7 animals (n 5 per group) at 21
weeks post-injection in 10% w/v 0.5 M triethylammonium
bicarbonate (iTRAQ kit, Applied Biosystems) containing 0.1%
SDS and Complete protease inhibitors (Roche Applied Sci-
ence). The protein concentration was estimated using protein
assay from Bio-Rad and 100 g from NBH and ME7 homoge-
nates isotopically labeled using iTRAQ multiplex reagents
(Applied Biosystems) as described by us and others (25, 26).
The lysates were reduced with 2.5 mM tris(2-carboxyethyl)-
phosphine at 60 °C for 1 h and then alkylated using 10 mM
methylmethane-thiosulfonate for 10min at RT. These samples
were proteolytically digested using trypsin at 37 °C for 20 h and
lyophilized in vacuo before resuspension in 20 l of 0.5 M tri-
ethylammonium bicarbonate. iTRAQ reagents 115 and 117
were resuspended in 70l of ethanol and added to theNBHand
ME7 samples, respectively. This mixture was incubated at RT
for 1 h before being quenched with 5 volumes of 0.1% TFA in
water. Labeled samples were pooled and submitted to strong
cation exchange fractionation on a Dionex Ultimate HPLC sys-
tem (Dionex-LC Packings, Sunnyvale, CA) using a Phenome-
nex Luna, 5 m, strong cation exchange column (150  4.6
mm, inner diameter). Forty fractions were collected at 200
l/min and dried in vacuo. These fractions were reconstituted
in 30 l of 5% acetonitrile/water prior to nanoLC-MS/MS
analysis.
NanoLC Tandem Mass Spectrometry—NanoLC-MSMS was
performed using a CapLC system (Waters, Manchester, UK)
coupled to a Streamselect micro-column switching module
(Waters) on line to a Q-Tof Global Ultima (Waters). One-third
of each sample was loaded via an autosampler onto a PepMap
RP-C18 guard column (5 300minner diameter, Dionex) for
pre-concentration and desalting before being resolved by nano-
reverse phase C18 PepMap analytical column (150  75 m
inner diameter, Dionex). Separation was achieved by forming a
gradient of 5–85% solvent B (solvent A: acetonitrile/water, 5:95
(v/v), 0.1% formic acid (v/v); solvent B: acetonitrile/water, 95:5
(v/v), 0.1% formic acid (v/v)) over 100 min. The flow rate was
maintained at 200 nl/min and electrosprayed into the mass
spectrometer using a Z-spray nanoLC source (Waters). The
mass spectrometer was operated in a data-directed acquisition
mode. Survey scans were acquired from 350 to 1700 m/z in
positive ion mode with the MS to MS/MS switching, including
precursor ion intensity and charge state. MS/MS spectra were
acquired from 50 to 1700 m/z, and the collision energy varied
according to charge state. The RF lens was adjusted for optimal
detection of the lowm/z reporter ions.
Data Analysis—ProteinLynx Global server was used to pro-
cess MS/MS data to generate peak lists. Peak lists were submit-
ted to MASCOT (Matrix Science, London, UK) and searched
against a FASTA format of the mouse NCBI protein database
using the following search parameters: 150 ppm peptide toler-
ance; 0.25-Da MS/MS peptide tolerance; 1 maximum missed
cleavage; variable methionine oxidation, and two fixed and one
variable modification for the iTRAQ chemistry. Only peptides
above a 70% confidence were saved for identification and quan-
tification. All spectra of identified proteins were manually
checked to ensure that at least three y- and related b-ions were
present. Reporter ion intensities were extracted from the cor-
responding MS/MS spectra using an in-house script, and
reporter ions below an intensity threshold of 20 counts were
excluded. Peptides ratios that are blank, 0, or9999 were also
removed. We then manually re-inspected each case to ensure
any such value was not from an intrinsic biological effect and
that protein identifications were based on accurate assignment
of MS/MS fragment ions. Based on these criteria, we found no
evidence that a peptide could show an expression value of
9999 (27, 28). The relative amount of a peptide in each sample
was calculated by dividing the peak areas at 117.1 by the
observedmass atm/z 115.1. Peak areaswere corrected for over-
lapping isotopes per the manufacturer’s instructions. These
ratios were ensembled and plotted on a correlogram.We used a
self-imposed 2-fold cutoff for reporting a protein as showing
significance. The rigorous cutoff was set because a number of
the proteins that satisfy criteria for inclusion were achieved on
the basis of individual peptides.Moreover, we saw limited tech-
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nical variations in the prior iTRAQ studies we have conducted
(26, 29). This cutoff is more stringent than the 1.3-fold used by
several others (27, 30).
Manipulation of Dissected Hippocampus—Dissected hip-
pocampi fromNBH andME7 animals 8, 13, and 21 weeks post-
inoculation (n 5 per group) were homogenized in 10 volumes
of PBS (containing 0.11% diethyl pyrocarbonate) and split and
into 2 equal aliquots, which were stored at 80 °C. Subse-
quently, total protein and total RNAwere extracted from these
samples, respectively, allowing for correlative protein and
mRNA expression to be performed on the same tissue from a
single animal.
Hippocampal Protein Extraction andAnalysis—In our previ-
ous studies, there was no marked difference in the protein
expression in NBH animals across disease time points so we
used a pool of 8-, 13-, and 21-week NBH samples as control
(NBH control, n 15), which we compared with ME7 animals
at 8, 13, and 21 weeks post-inoculation (n 5 per group). Pro-
tein/chemical samples were combined with an equal volume of
lysis buffer (4% SDS, 40 mM HEPES, 200 mM KCl containing a
mixture of phosphatase inhibitors and complete protease
inhibitor mixture). Samples were incubated for 1 h and then
centrifuged at 15,000 rpm for 30 min at 4 °C. The supernatant
was collected as the SDS-soluble fraction and the protein con-
tent quantified using the protein assay from Bio-Rad. These
SDS extracts of total hippocampal proteins samples were sub-
sequently diluted into sample buffer, resolved by PAGE, and
transferred to nitrocellulose prior to analysis by Western blot-
ting (31).
Western Blotting Procedure—Membranes were blocked in
5% nonfatmilk for 1 h at room temperature and then incubated
in TBS containing 0.1% Tween 20 and one of the following
primary antibodies: anti-cow glial fibrillary acidic protein poly-
clonal antibody (1:5000; DAKO Laboratories); anti-EAAT-2
polyclonal antibody (1:1000; Sigma); anti-Clusterin mAb
(1:1000; Cell Signaling); anti-peroxiredoxin-6 mAb (1:1000;
Cell Signaling), and 6H4 anti-PrP mAb (1:5000; Prionics).
Membranes were incubated with the primary antibodies over-
night at 4 °C. The blots were washed and incubated for 1 h with
fluorescently labeled anti-sheep secondary antibody at room
temperature. Protein band intensities were analyzed using a
LiCor Odyssey infrared detection system (LI-COR Biosci-
ences), following the manufacturer’s guidelines, and normal-
ized to total protein loading, as measured by colloidal Coomas-
sie Blue staining by an approach described elsewhere (32).
Total RNA Extraction and TaqMan Real Time PCR—Total
RNAs were extracted from the homogenized hippocampal tis-
sue that was divided into aliquots for protein and transcript
analysis as described above. Aliquots of these homogenates
were extracted with RNeasy (Qiagen). After treatment with
RNase-free DNase (Promega), the concentration of total RNA
purified for each samplewasmeasured using aNanoDrop spec-
trophotometer. 400 ng of total RNA was reverse-transcribed
into cDNA in a 20-l final volume using the iScript reverse
transcriptase kit (Bio-Rad). The optimal PCR conditions for
each transcript investigated were experimentally determined
using the temperature gradient function of the DNA Engine
Opticon 2 (MJ Research, Waltham, MA) (data not shown).
Reactions were performed in the DNA Engine Opticon 2 real
time PCR detection system (MJ Research), and real time PCR
efficiencies were calculated from the given slopes in the Opti-
con 2 Monitor software (MJ Research). Preliminary experi-
ments ensured amplificationswere analyzed in the linear range.
The following primer and probe sequences were designed with
Primer Express software (Applied Biosystems): EAAT-2
(primer sequence 5-CCC AGC GCC GGG CTG GTC-3,
5-GGA CTG CGT CTT GGT CAT TTC G-3, and 5Fam-
GCT GTG GGC CTG CCA ACG-3Tamra probe); peroxire-
doxin-6 (primer sequence 5-CCCGGAGGGTTGCTTCTC-
3, 5 CGT GGT GGC AGG GTA GAG GA-3, and 5Fam-
CCA GTG TGC ACC ACA GAA C-3Tamra probe); PrP
(primer sequence 5-AGT CCA ATT TAG GAG AGC CAA
GC-3, 5-TCA GTC CAC ATAGTC ACAAAGAGG-3, and
5Fam-AGC AGC CAG TAG CCA AGG TTC GCC-3Tamra
probe); GFAP (primer sequence 5-TTT CTC CAA CCT CCA
GAT CC-3, 5-CCG CAT CTC CAC AGT CTT TA-3, and
5Fam-CCAGCCTGGACACCAAATCCG-3Tamraprobe),
and Clusterin (primer sequence 5-AGGAGCTGAACGACT
CGC T-3, 5-GCT TTT CCT GCG GTA TTC C-3, and
5Fam-CAG AGC AGT ACA AGG AGC TG-3Tamra probe).
mRNA expression was quantified using a TaqMan RT-PCR kit
(Applied Biosystems). EAAT-2, peroxiredoxin-6, PrP, GFAP,
and Clusterin mRNA expression in the different samples were
normalized for GAPDH gene expression levels with the rodent
GAPDH reagents kit (Applied Biosystems), specifically for
standardizing gene expression levels to a housekeeping gene,
and the results were expressed as relative fold increase or
decrease between treatments (ME7/NBH).
Mouse Clusterin ELISA—The concentration of Clusterin in
plasma from21-weekNBHandME7 animals was assayed using
a commercial mouse quantitative ELISA kit (mouse Clusterin
Quantikine ELISA kit, R&D Systems). All reagents, standard
dilutions, and samples were prepared as directed in the manu-
facturer’s instructions. Briefly, sera were diluted 1:2000 with
calibrator diluent buffer and then added to the ELISA plate in
duplicate and incubated for 2 h at room temperature on a hor-
izontal orbital microplate shaker set at 500 rpm. After incuba-
tion with the mouse Clusterin conjugate, the reaction was
stopped and analyzed spectrophotometrically at 450 nm. The
concentration of Clusterin was determined relative to a stand-
ard curve generated with recombinant Clusterin. A positive
control sample was provided with the kit, which had an assay
range of 0.781–50 ng/ml.
Histology and Immunohistochemistry—Immunohistochem-
istry analysis was performed on (10 m) paraffin-embedded
tissue sections from NBH and ME7 animals using antibodies
directed against (PrP, synaptophysin, GFAP, Clusterin,
EAAT-2, and Prdx6) with previously described protocols (22,
24). In particular, histological detection of PrPSc was achieved
by taking coronal sections from NBH and ME7 animals and
immunostaining with anti-PrPmAb 6H4 following formic acid
and autoclaving treatment to remove PrPc leaving only PrPSc
species (22, 24). Specific binding was detected using biotiny-
lated secondary antibodies, avidin-biotin-horseradish peroxi-
dase complex kit, and 3,3-diaminobenzidine as a substrate
(Vector Laboratories) to visualize antibody localization accord-
Quantitative Proteomics Analysis of Prion-infected Tissue
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ing to the manufacturer’s instructions. Nuclei were counter-
stained with hematoxylin. Following double antibody staining
of some sections, fluorescent anti-mouse, -rabbit, or -goat sec-
ondary antibodies were used to visualize the proteins. Co-local-
izationwas demonstratedwith the co-localization finder plugin
of the ImageJ processing package (National Institutes ofHealth,
Bethesda, MD).
Statistical Analysis—All statistical analyses were made using
Graph Pad Prism 4.0 (Graph Pad Software Inc., San Diego). A
one-way analysis of variance test was applied to biochemical
data. A Student’s t test together with Welch’s correction was
used to compare mRNA expression data and Clusterin levels.
RESULTS
Protein Profiling, iTRAQ, and Mass Spectrometry—In the
ME7 model of prion disease, proteinase K-resistant PrPSc is
readily detected at late-stage disease and is widespread
throughout the hippocampus. These features were demon-
strated in the cohorts of animals set up for this study and are
depicted in the immunocytochemical staining of PrPSc (Fig. 1,A
and B). In addition, in animals at an advanced stage of disease,
the hippocampal formation is clearly reduced in volume, and
there is hippocampal cell loss indicated by thinning of the stra-
tum pyramidal of CA1 and a decrease in the intensity and dis-
organization of staining of several synaptic markers, including
the synaptic vesicle protein synaptophysin (Fig. 1, C and D).
Further Western blotting from tissue extracts reveal the dis-
ease-induced accumulation of PrPSc and the robust reduction
in synaptic proteins (Fig. 1E). Animals displaying this neuronal
degeneration show overt changes in a number of affective, cog-
nitive, and motor behaviors and exhibit piloerection and
hunched behavior in the home cage (22).
We pooled hippocampi from five 21-week-old ME7 animals
and compared them with age-matched NBH animals. We
extracted total protein from membrane homogenates by solu-
bilizing in SDS-containing buffers compatible with affinity
labeling with iTRAQ (Applied Biosystems). This involved an
upper SDS concentration of 0.1%. We profiled and quantified
differences using mass spectrometry. The MS/MS approach
causes a fragmentation of the isobaric tags from the parent
peptide, and the signals from these are captured at the low
molecular weight end of the spectrum. This relative abundance
of the signal from the isobaric tags affords quantification of
individual proteins from the samples from ME7 and NBH ani-
mals, respectively. In the highmolecularweight end of the spec-
trum, the fragmentation of the parent ion provides a signal that
is used to identify protein. In the current analysis, NBH animal
control samples were labeled with the 115 isobaric tag, and the
ME7 animal samples were labeled with the 117 tag. Many pep-
tides fragmented to reveal no change in relative abundance, and
this is illustrated in Fig. 2, middle panel. Other peptides that
were fragmented show clear differences in their relative expres-
sion. Among the more striking changes were those associated
with several peptides derived from GFAP; the raw signal from
one of the peptides for this protein is also shown (Fig. 2, top
panel).
Changes of Peptide Abundance in the Hippocampus of NBH
or ME7 Animals—The complete MS/MS spectra collected
were first subjected to manual analysis to eliminate spectra in
which the NBH- orME7-related signal was less than 20 counts.
The remaining spectra were queried against a mouse database,
and the majority of the peptides matched with high MASCOT
ion scores (p 0.05). OurMS/MS analysis is based upon quan-
titative peptide data from 200 individual hippocampal pro-
teins whose expression changes or remains the same (Fig. 2,
bottom graph). Using a 2-fold change as a cutoff to score
changes in protein expression, we found three proteins were
down-regulated and eight proteins up-regulated in ME7 ani-
mals relative toNBHanimals (Table 1). The rigorous cutoff was
set because a number of the proteins that satisfy criteria for
inclusion were achieved on the basis of single peptides. The
displayed proteins did not include synaptophysin, which we
previously showed had reduced expression by quantitative
immunoblotting (Fig. 1E). This supports the notion that
the current analysis favored the detection of proteins that were
FIGURE 1. Basic synaptic architecture in the ME7 model. Representative
immunohistological staining using 6H4 PrP monoclonal antibody on auto-
claved formic acid-treated coronal sections from NBH control animals (A) are
comparedwithME7animals (B, showing accumulatedmisfoldedprion (PrPSc;
brown stain)). Synaptophysin monoclonal antibody (mAb SY38) staining of
normal hippocampal strata in NBH animals (C) are compared with ME7 ani-
mals (D, showing synaptic disorganization and neurodegeneration in late
stageprionhippocampal tissue). Labelingof hippocampal layers is as follows:
Or, oriens layer; Rad, stratum radiatum; LMol, lacunosum molecular layer;
MoDG, molecular layer dentate gyrus; GrDG, granular layer dentate gyrus;
PoDG,polymorph layer dentategyrus. Scale bar,200m. E showsa represent-
ative Western blot of total brain homogenates from normal (NBH) or ME7-
inoculatedmice showing disease-associated increase of PrP (mAb 6H4) and a
decrease in synaptic marker protein synaptophysin (mAb SY38) in ME7 com-
pared with NBH animals.
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relatively abundantly expressed in the extracted hippocampal
proteome. Brief descriptions of the function of the differentially
regulated proteins are presented in Table 2. Further informa-
tion about the identified proteins, which did not change or
showed potential differential regulation below our criteria, are
listed in Gray (33).
Astrocytic Response in ME7 Model—GFAP was among the
most robustly up-regulated protein based on the relative inten-
Quantitative Proteomics Analysis of Prion-infected Tissue
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sity of a number of peptides independently identified. Further-
more, the intensity of the MS signal in NBH samples also indi-
cated that the protein is among the more abundant proteins
profiled even in control samples. Immunocytochemical stain-
ing for GFAP in hippocampal sections from NBH and ME7
animals shows the abundance of astrocytes in both cohorts and
a markedly increased staining in theME7 samples (Fig. 3,A–D,
compared with E–H). Three of the other candidate proteins
that we observed to be up-regulated in ME7 animals included
Clusterin, EAAT-2, and Prdx6, which are all known to be pre-
FIGURE 2. Representative MS/MS spectra for two peptides identified in this analysis are shown. Top and middle panels, 100 g of homogenate was
denatured, reduced/alkylated, trypsin-digested, and labeled with iTRAQ reagents 115.1 and 117.1 in parallel. Both reagents have a reporter group to label
primary amines as well as a balance arm. The resulting labeled, complex peptide mixture was mixed and separated by cation exchange chromatography.
Following collision-induced dissociation MS/MS analysis of the precursor ion, the reporter groups appear as distinct ions (m/z 115–117), and the relative
concentrationof thepeptides is derived fromthe relative intensitiesof the reporter ions.MS/MSspectra for Syntaxin-bindingprotein andGFAPare shown,with
the peptide fragmentation and isobaric tag fragmentation that are used to identify (left panel) and quantify (right panel) protein expression, respectively. All
signalswith reporter ion intensity of20were ignored. This analysis produced robust signals encompassing 2–9 peptides from200 individual hippocampal
proteins. Correlogram showing relative expression of over 200 hippocampal proteins in NBH and ME7 hippocampal extracts. Bottom panel, over 200
proteins were predicted using bioinformatics tools. We used a 2-fold change as a cutoff to score changes in protein expression; eight proteins were
identified as up-regulated and three proteins as down-regulated in ME7 compared with NBH animals. Four of the up-regulated proteins (GFAP,
Clusterin, EAAT-2, and Prdx6) are components of astrocyte.
TABLE 1
Proteins differentially expressed in NBH andME7 hippocampal extracts
Selected up-regulated proteins in ME7 are compared with NBH samples. Only proteins with ratios at least 2-fold higher or lower than the average value (0.9) were
considered. Candidate proteins are reported with their associated accession number (in italics below). Eight peptides were up-regulated in ME7 compared with NBH.
Selected down-regulated proteins in ME7 are compared to NBH samples. Three peptides down-regulated in ME7 compared with NBH animals are listed.
Up-regulated proteins
-Fold
change Peptides
emPAI
score Down-regulated proteins
-Fold
change Peptides
emPAI
score
Cytokine-like-1 EF108311 4.3 MAEVDTLK 21.53 S-Acetyltransferase NM145614 30.5 ILVPEGTR 27.37
Clusterin NM013492 2.8 ASGIIDTLFQDR 38.73 GLETIASDVVSLASK 27.37
GFAP X02801 3.8 ALAAELNQLR 63.94 Synaptotagmin 1 or 5 NM009306 22.9 LTVVILEAK 44.02
DNFAQDLGTR 125.90 TLVMAVYDFR 59.12
ESASYQEALAR 64.51 VPTAGK 28.69
FADLTDAASR 155.76 Ubiquitin-conjugating enzyme U82627 13.6 VILQELR 25.38
IYEEER 64.51
LDQLTANSAR 125.90
LEAPDADELPR 176.95
LQDETNLR 155.76
Lectin, mannose binding-2 NM025828 3.2 DNVDDPTGNFR 20.93
MAP-1A AF182208-12 8.4 AVLDALLEGK 23.89
EIQGLFEEK 59.85
Nesprin-2 NM001005510 10.4 MLQQKSR 20.24
LQLETMNQK 20.24
Peroxiredoxin-6 NM174643 2.4 NFDEILR 26.99
SVDEIR 23.79
EAAT-2 AB007810 35.0 MQEDIEMTK 57.81
SELDTIDSQHR 24.29
TABLE 2
Function of proteins differentially expressed in NBH andME7 hippocampal extracts
Proteins are reported with their associated accession number (in italic below).
Function
Up-regulated proteins
Cytokine-like-1 (Cytl1) EF108311 Candidate cytokine with unknown function that was originally identified in bone marrow-derived
CD34-positive cells but was predominantly expressed in chondrocytes and cartilage (106).
Clusterin (Clu) NM013492 Expressed in a variety of tissues where it binds to cells, membranes, and hydrophobic proteins. It
is associated with apoptosis and is up-regulated in osteoarthritis and recently highlighted in
GWAS for Alzheimer disease (35).
GFAP X02801 GFAP is a class-III intermediate filament (37).
Lectin, mannose binding-2 NM025828 Recognizes glycosylphosphatidylinositol anchors or sugar residues of glycoproteins and
glycolipids and may be involved in the sorting or recycling of proteins and lipids and
endoplasmic reticulum-to-Golgi transport of selected proteins (107).
Microtubule-associated protein 1A (MAP-1A)
AF182208-12
Structural protein involved in the filamentous cross- bridging between microtubules and other
skeletal elements (108).
Nesprin-2 NM001005510 Maintenance of nuclear organization and structural integrity. Connects nuclei to the cytoskeleton
by interacting with the nuclear envelope and with F-actin in the cytoplasm (109).
Peroxiredoxin-6 (Prdx6) NM174643 It may play a role in the regulation of phospholipid turnover as well as redox regulation of the
cell (34).
EAAT-2 AB007810 Solute carrier family 1 (glial high affinity glutamate transporter), member 2; it transports
L-glutamate and also L- and D-aspartate. Acts as a symport by co-transporting sodium (36).
Down-regulated proteins
S-Acetyltransferase NM145614 Component of the pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate
to acetyl-CoA and CO2 (110).
Synaptotagmin 1 or 5 NM009306 Ca2-dependent synaptic vesicle-trafficking protein, involved in regulation of glial glutamate
release (111, 112).
Ubiquitin-conjugating enzyme U82627 Regulation of sumoylation with the help of E3 ligases like RANBP2 or CBX4 (63).
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dominantly expressed in astrocytes (Fig. 3, I–N) (34–36).
Immunoreactivity for thesemolecules is also observed in astro-
cytes outside the hippocampus (data not shown).We used dou-
ble immunocytochemistry of Prdx6 and GFAP to confirm
whether this protein is expressed and induced in astrocytes or
other cells in ME7 animals. Our data revealed co-localization
of Prdx6 and GFAP albeit with weaker immunoreactivity of
Prdx6 than GFAP; Prdx6 was expressed in NBH tissue (Fig. 4,
A–D) but was markedly increased in theME7 animals (Fig. 4,
E–J). No cells other than astrocytes appear to express Prdx6.
ImageJ co-localization is shown in white at the far right,
illustrating the pixels having both significant red and green
signals (Fig. 4, I–J).
Estimating Proliferated Changes in ME7—The increased
expression of the individual proteins could simply reflect an
increase in astrocyte number as a consequence of disease.
There is evidence showing that GFAP content is increased
in astrocytes during reactive gliosis (37, 38) and also evidence
astrocytes may proliferate in some disease states (39). To
address this issue, we used Ki67 as amarker of cell proliferation
and GFAP double labeling to investigate if there was prolifera-
tion of astrocytes during ME7 disease. Using this approach, we
observed that in NBH animals Ki67 immunoreactivity is low
(data not shown) relative to ME7 animals (Fig. 5). Although
there was increased Ki67 in ME7 animals, we did not observe
significant co-localization of Ki67 and GFAP (Fig. 5, arrow-
heads). In instances of Ki67 and GFAP apposition, this staining
appeared in associated cells (Fig. 5, arrows). This is consistent
with our recent report inwhichwe demonstrate that themicro-
glial population was the main cell type proliferating during
prion disease (21). This suggests that the increased level of the
astrocytic protein in the hippocampus of ME7 animals is not
determined by their proliferation (Fig. 5).
Cellular Regulation of Glial Protein Expression in ME7
Disease—We investigated progressive changes in the identified
glial genes and their expressed proteins across disease. Five hip-
pocampi from ME7 and NBH animals at 8, 13, and 21 weeks
were homogenized as individual samples and divided in 2 ali-
quots from which either protein or total RNA was extracted.
For quantitative Western blot analyses, we used a pool of SDS
buffer-extracted 8-, 13-, and 21-week NBH hippocampal
homogenates as control (NBH control), which was compared
FIGURE 3. Reactive astrocytes in the hippocampus of ME7 animals. Pho-
tomicrographs illustrate GFAP expression in NBH and ME7 animals at 21
weeks. Nuclei were counterstained with hematoxylin. GFAP immunoreactiv-
ity in astrocytes in the hippocampal layers of NBH animals (see arrowheads in
A–D,5,10,20, and40 magnifications, respectively) is shown. At this
stage, there is minimal GFAP staining in the cortical regions of NBH animals
(data not shown). ME7 animals were strongly positive for GFAP, particularly
within the swollen astrocytic processes (see arrowheads in E–H, 5, 10,
20, and40 magnifications, respectively), and at this stage of the disease,
there is strong GFAP staining in the cortex (data not shown). Labeling of
hippocampal areas: hippocampal formation (HPF); dentate gyrus (DG); poste-
rior thalamic nucleus (Po); cornu ammonis area 1 (CA1); stratum radiatum
(SRad). Brain sections were stained with antibodies against the other astro-
cyte-associated proteins highlighted in the proteomic analysis, and repre-
sentative images are shown of the stratum radiatum inNBH andME7 animals
immunostained for Clusterin (I and J), EAAT-2 (K and L), and Prdx6 (M and N)
(arrowheads are directed to examples of immunoreactive astrocytes). Scale
bar, 20 m.
FIGURE 4. Prdx6 staining of hippocampus in NBH andME7 animals. Rep-
resentative fluorescent images to illustrate Prdx6 expression in astrocytes in
the CA1 hippocampal region of NBH and ME7 animals. A–D, co-staining of
Prdx6 with GFAP in NBH animals. A, GFAP, Texas red; B, nuclei, DAPI blue; C,
Prdx6, FITCgreen; andD,merged image. Scale bar,100m. E–H,ME7animals.
E, Prdx6, FITC green; F, nuclei, DAPI blue; G, GFAP, Texas red; and H, merged
image. Scale bar, 75 m. I, representative image showing CA1 hippocampal
region of high expression coincidence of Prdx6 and GFAP (arrowheads) in
ME7 animals are shown at a higher magnification. ImageJ co-localization is
shown in white in the far right, illustrating the pixels having both significant
red and green signal (J). Scale bar, 50 m.
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with 13- and 21-weekME7 animals and probed with antibodies
against PrP, GFAP, Clusterin, EAAT-2, and Prdx6 (Fig. 6,A–J).
The presence of an increasing level of PrPc/PrPSc in each sam-
ple was indicated by the increasing anti-PrP antibody immuno-
reactivity and the emergence of high order oligomers that resist
dissociation by SDS at both the middle and late stages of the
disease (Fig. 6,A and F, p 0.01) (32). GFAP immunoreactivity
increased with the disease (Fig. 6B), and quantification showed
a significant increase relative to NBH control at the 13-week
time point (Fig. 6B, p 0.01) that further increased by 21weeks
(Fig. 6B, p 0.01).
Immunoreactivity for Clusterin (Fig. 6C) is smeared in keep-
ing with previous data for this highly glycosylated protein (40).
Nevertheless, we observed a progressive increase in the immu-
noreactivity for Clusterin, which resolves as an apparent ungly-
cosylated band (arrow in Fig. 6C) and the various glycosylated
states (smear in Fig. 6C) that progressively increase at 13 and 21
weeks.We quantified the intensity of the unglycosylated/glyco-
sylated protein band at 45 kDa and showed that this increase
was significant relative to NBH control at both 13 and 21 weeks
(p  0.01). Similarly, EAAT-2 showed increased expression at
13 weeks that progressed further at 21 weeks (Fig. 6D), and
quantification of these blots showed that EAAT-2 expression is
significantly increased at 13 weeks and progresses to an ele-
vated level at 21 weeks (Fig. 6I, p  0.05 and p  0.001,
respectively). Prdx6 expression was also significantly ele-
vated at the late stage of the disease (Fig. 6, E and J, p 0.01)
consistent with the independent identification of its induc-
tion in the iTRAQ analysis and by immunohistochemistry
(Fig. 3, L andN). In contrast, this protein does not seem to be
significantly elevated at the earlier time point; thus, unlike
GFAP and EAAT-2, Prdx6 is only significantly induced later
in ME7 disease.
Transcriptional Changes in Clusterin, Peroxiredoxin-6, PrP,
GFAP, and EAAT-2—Previous studies indicate that the
increased expression of GFAP is directly related to a transcrip-
tional response. However, the differential increased expression
in PrP, Clusterin, and Prdx6 identified in this study indicates
that there may not be simple relationship between transcrip-
tion and protein expression. TaqMan RT-PCR was performed
to quantify the expression of the mRNA species. The expected
PCR product size for each gene product was initially confirmed
by agarose gel electrophoresis, and additionally the no-tem-
plate controls showed no amplification (data not shown). The
RT-PCR analysis compared changes in PrP, GFAP, Clusterin,
EAAT-2, and Prdx6 mRNAs of ME7 and NBH animals (Fig. 7,
A–E). It should be noted that these mRNAs are taken from the
same tissue used to measure protein expression levels. Despite
the large increase in PrP protein, there is no differential change
in the PrPmRNAbetweenNBHandME7 animals (Fig. 7A).We
observed that in ME7 animals at the late stage of the disease,
GFAP and Clusterin transcription was increased 	5-fold
(Fig. 7, B and C, p  0.001 and p  0.05, respectively), com-
pared with NBH. There was no difference in the levels of
EAAT-2 transcript at the late stage of the disease between
ME7 and NBH animals, although there was a significant
increase in EAAT-2 mRNA at the middle stage of disease,
compared with NBH (Fig. 7D). The data suggest that this is
due to low level of expression in the NBH group at this time
point. Expression values for Prdx6 mRNA were considerably
lower than those of the other genes (Fig. 7E) and did not
increase with disease progression. Increased Prdx6 protein
expression is not supported by transcriptional up-regulation
of Prdx6 mRNA.
Does Glia-produced Clusterin Appear in Blood as a Potential
Biomarker?—We have previously shown that a number of typ-
ical acute phase proteins serum amyloid A, complement C3,
pentraxin 3, and 2-antiplasmin are induced in the brain of
animals with prion disease, but there is no induction ofmessage
in the liver despite the presence of systemic deposition of PrPSc
(19). The induction of the acute phase protein Clusterin in
astrocytes is of particular interest because it has been suggested
that this protein may be a useful serum biomarker in patients
with AD (41). Thus, using a commercially available sandwich
immunoassay, we examined the utility of Clusterin as a candi-
date serum biomarker for prion disease. We measured its con-
centration in samples from NBH and ME7 animals, and we
showed that serum levels of Clusterin were unchanged (Fig. 8A,
72.02 
 9.5 and 83.17 
 4.5 g/ml). Despite the significant
increase of this protein in the hippocampus, cortex, and tha-
lamic brain regions of animals with prion disease, the protein
does not leave the brain in sufficient amounts to be detected in
serum.We also examined whether systemic infection with Sal-
monella typhimurium will alter the levels of Clusterin (42).
Overall infection with Salmonella increased the levels of circu-
latingClusterin inNBHandME7 animals by 40% (p 0.05) and
35% (p  0.215), respectively, compared with uninfected ani-
mals, but therewas no difference betweenNBH Salmonella and
ME7 Salmonella animals (Fig. 8A, 112.1 
 14.3 and 112.4 

21.6 g/ml).
DISCUSSION
The ME7 model of prion disease has generated increasingly
detailed insights into the evolution of the pathology of this neu-
rodegenerative disease and underlying mechanisms (21, 22,
43–45). In this study, we have investigated the hippocampal
proteome at late-stage prion disease. This study uses the
iTRAQ technique to simultaneously identify and quantify the
FIGURE 5. Expression of the proliferation marker Ki67 in the hippocam-
pus of ME7 animals and its co-localization with astrocyte marker GFAP.
Representative images are from coronal sections showing hippocampal
region stratum radiatum (SRad) (A) and dentate gyrus (DG) of ME7 animals
stained for Ki67 cells, FITC green and GFAP, Texas red (B). Majority of Ki67
staining (FITC green) was restricted to the nucleus (arrowheads) and largely
distinct from the GFAP (Texas red). A few Ki67 cells were apposed to GFAP
(arrows), but this was associated with rather than within the GFAP-positive
cells. Scale bar, 100 m.
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hippocampal proteome in animals with ME7- induced prion
disease (25, 26, 46). This analysis produced robust signals
encompassing 2–9 peptides from 200 individual hippocam-
pal proteins. Using a 2-fold change as a cutoff to score changes
in protein expression, we identified eight proteins as up-regu-
lated and three proteins as down-regulated in ME7 animals.
We specifically focused on four of the up-regulated proteins
(GFAP, Clusterin, EAAT-2, and Prdx6), which are known to be
expressed by astrocytes (47, 48). GFAP up-regulation is a dom-
inant feature of the proteome of prion-diseased brain tissue (32,
49, 50), and the other three proteins all independently associate
with astrocytes and show differential increases in expression as
the prion disease progresses to end stage. There is a steady
increase of GFAP, Clusterin, and EAAT-2 throughout the dis-
ease time course with a more restricted onset of increased
expression exhibited by Prdx6. The regulation of glial expressed
molecules is also distinct when considering the comparison of
protein and mRNA expression. These analyses were made by
Western blotting and transcriptionally measuring gene expres-
sion in protein andmRNA extracted from the same tissue. This
shows that the increase in certain glial proteins is matched by
transcriptional regulation, whereas in the case of Prdx6, the
protein increase seems independent of a transcriptional
response. Some of these changes described above are supported
by observations in microarray time course studies from other
prion strains (50, 51).
The observation that Ki67 staining does not coincide with dis-
ease progression shows that the changes in protein expression we
have investigated are taking place within a numerically constant
population of astrocytes.We observed that Ki67 labeling of astro-
cytes was negligible, which contrasts with microglia that have a
pronounced proliferative response (21). Previous investigations of
the microglial response have shown that they contribute to the
pathogenesis of prion disease (24, 52). Selective inhibition of
microglia proliferation slowed disease progression (21). However,
less is known about the roles played by the astroglia.
FIGURE 6. Western blot analysis to verify the protein changes observed from MS analysis. Quantitative Western blotting of astrocytic proteins in hip-
pocampal homogenates (brain equivalent, 20 g) from normal animals (pooled NBH controls) compared with ME7 animals (13 and 21 weeks) Samples were
probed for the presence of PrP (mAb 6H4) and candidate up-regulated proteins (GFAP, EAAT-2, Clusterin, and Prdx6). A–E shows representative experimental
blots. 1st lanes, NBH control; 2nd lanes, 13-week ME7; and 3rd lanes, 21-week ME7. F–J, densitometric data in each bar represents means 
 S.E. from n  5
animals. The error bar represents direct comparison between the protein expression in NBH control samples and the ME7 animals. * signifies p  0.05; **
signifies p 0.01; *** signifies p 0.001.
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In vitro studies have shown that both neurons and astrocytes
are capable of sustaining efficient prion propagation independ-
ently, leading to the production of PrPSc (53), but the kinetics of
their production in resting and activated glia have not been
studied. Neuronal synthesis of PrPc has been shown to be
important, as reversal of prion disease is possible through selec-
tive reduction of neuronal PrPc in mice with established prion
infection (54). However, there is abundant evidence that non-
cell autonomous influences are intimately involved in disease
pathogenesis. PrPc expression in astrocytes is critical for sus-
taining cell-to-cell interactions, neuronal differentiation, and
survival (55), but astrocytes accumulate prion aggregates lead-
ing to reactive astrocytosis (56) that spares astrocytes with
bystander effects on PrPc-null neurons (57).
Astrocyte-specific expression of hamster prion protein ren-
ders PrP knock-out mice susceptible to prion disease despite
the lack of neuronal PrPc (15). Others confirmed that PrP
expression on neurons or astrocytes was sufficient for prion-
induced neurodegeneration (58), but PrPc expression on follic-
ular dendritic cells is also important for prion replication (59,
60). Equally important in disease pathogenesis is the role of
neuron-glia cross-talk likely initiated by an interaction between
microglia-secreted molecules and astrocytes, which then
impact on neurons (61, 62). This highlights glial cells playing a
crucial part in disease as has been observed in several other
neurodegenerative conditions (16, 64).
The proteins identified in the proteomic screen exhibit func-
tions that support a potential role as modulatory determinants
of disease progression. Although GFAP is essentially a struc-
tural protein, its induction in astrocytes underpins important
morphological changes that the astrocytes use to extend their
sphere of influence and facilitate cellular structures and func-
tion by determining the shape and controlling themovement of
these cells (65). In the case ofClusterin, several associated activ-
ities suggest it regulates neurodegeneration (66, 67). Clusterin
functions include extracellular protein chaperoning, lipid car-
riage, and participation in stress responses, all of which are
neuroprotective. In the context of prion disease, Clusterin
shows an ability to bind misfolded protein with high avidity
(68), and it has been shown to reduce the cytotoxicity of amy-
loid- in AD (69). However, Clusterin is also known to collab-
orate with the complement cascade in both the CNS and the
periphery, an interaction that may help with misfolded protein
clearance (70, 71). The role played by these pathways and their
potential convergence with each other has received a renewed
interest following the observation that Clusterin and the C1q
receptor, an early component of the complement cascade, are
significant genetic determinants of late onset AD (72, 73).
Clusterinwas found to be increased in plasmaofADpatients,
and the levels were reported to be associated with severity and
FIGURE 7. TaqMan RT-PCR. TaqMan RT-PCR analysis of EAAT-2, Prdx6, PrP,
GFAP, and ClusterinmRNAs inNBH is comparedwithME7 animals.A, PrPmRNA
appears unchanged, although the levels were higher at the mid-stage of the
disease.BandC,Clusterin andGFAP transcriptionwere increased	5-fold (*,p
0.05; ***, p  0.001, respectively), compared with NBH at the late stage of the
disease. D, there was no difference in the levels of EAAT-2 transcript at the late
stageof thedisease, althoughtherewasasignificant increase inEAAT-2mRNAat
the mid-stage of disease, compared with NBH. E, there was no transcriptional
regulation of Prdx6 associatedwith the disease propagation.
FIGURE 8.Measurement of Clusterin in serum. The levels of Clusterin were
measured by quantitative sandwich ELISA in serum of NBH and ME7 animals
with or without systemic S. typhimurium infection. S.E. values are shown, and
there were no statistical (ns) differences between NBH and ME7 animals in
both groups.
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progression of disease (41, 74, 75), but others disagree (76–78).
We examined whether changes in brain concentrations of
Clusterin in ME7 animals was reflected in serum. We tested
sera from 21-week NBH andME7 animals at a time point when
there was robust neurodegeneration and peripheral deposition
of PrPSc. Crucially, we could be certain that the animals had not
yet progressed to terminal disease, when urinary incontinence
could cause systemic inflammation sufficient to trigger hepatic
acute phase response independent of the ensuing neurodegen-
eration. Our results showed no difference in serum levels of
Clusterin betweenNBH andME7 animals. These data in which
peripheral confounds have beenwell controlled caution against
the idea that raised brain levels of acute phase proteins or cen-
trally produced components of innate immune cells can be
detected in serum.
There was a significant difference in serum Clusterin levels
between control and animals infected with S. typhimurium, but
there was no difference between cohorts of S. typhimurium-
infected NBH and ME7 animals (42). This shows that serum
Clusterin estimates are unsuitable as a biomarker for prion dis-
ease. Protein and mRNA levels of pro-inflammatory cytokines
like IL-1, IL-6, and TNF- are elevated in the brain, peripheral
lymphoid tissue, and serum of terminal prion animals (19, 79,
80). The macrophages, monocytes, and astrocytes responsible
for these signals can induce expression of acute phase proteins
like Clusterin (81, 82). Clusterin levels are elevated in synovial
fluid of rheumatoid arthritis and osteoarthritis patients (83, 84)
and in the cerebrospinal fluid of patients with AD, Parkinson
disease, andmultiple sclerosis (85–87), as well as in the urine of
patients with kidney injury or bladder cancer (88, 89). It cannot
be ruled out that an elevated level of Clusterin in the plasma of
ADpatients reflects systemic disease (90). The consensus is that
although acute phase proteins are highly sensitive indicators of
inflammation and tissue injury, they lack specificity (91, 92).
The induction of EAAT-2 and Prdx6 represents a coordi-
nated increase inmolecules that provide a neuroprotective role.
EAAT-2 is responsible for the majority of steady state gluta-
mate uptake in the brain (93), and the increased expression of
this molecule will buffer against the neurotoxic effect of ele-
vated extracellular levels of this transmitter (94). In other pro-
teinmisfolding diseases, there is a clear precedent for a targeted
disruption in EAAT-2 function (95); however, the significance
of glutamate toxicity in prion diseasemay bemore limited but is
less well understood. Evidence from a recent transcript analysis
of prion disease animals also suggests that excitotoxic signaling
may contribute to the ongoing disease process (96). This would
mean that EAAT-2 expression reflects an important secondary
effect to buffer glutamate that arises from the progressive pri-
mary neurodegeneration. In a similar way, Prdx6 belongs to a
family of 25-kDa peroxidases with a single redox-active cys-
teine thought to function as antioxidants (97, 98). Although
Prdx6 has a reported phospholipase A2 activity its role in the
glial response is likely to be as an antioxidant (99). Our analysis
of this protein and its mRNA, while supporting its appearance
in disease glial expression, suggests that it is regulated at the
level of protein.
We specifically focused on the astrocyte-related proteins in
this report, but the remaining up-regulated proteins are also of
interest and have been briefly described in Table 2. In particu-
lar, their potential role in mediating changes in innate immune
regulation and neuronal structural remodeling also suggests
the existence of possible new targets for therapeutic interven-
tion. Other prions strains (22L and 79a) exhibit some overlap-
ping behavioral deficits and neuropathology with ME7 (100,
101), but we have limited evidence that our biochemical obser-
vations inME7 prion disease are the same as in other strains. A
more detailed discussion of potential strain differences that
have not been investigated is beyond the scope of this report.
However, there is evidence that the proteins we have investi-
gated are also differentially regulated in other prion diseases
(32, 49–51,102–105). The current analysis, although restricted
to identifying and characterizing the most abundant compo-
nents of the degenerating hippocampal proteome, suggests a
complex, multifaceted glial response capable of a homeostatic
response that supports morphological, metabolic, proteostatic,
and neurochemical changes in the chronic degenerating brain.
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